SERPINC1 and COVID-19: Other examples could be provided by the phenomenon of thrombosis observed after administration of the AstraZeneca® [98] vaccine, possibly due to the inhibition of the synthesis of anti-thrombotic proteins, such as SERPINC1 and CRP, or by the specific mortality of diabetic patients with COVID-19 [99,100], possibly due to a decrease in the concentration of glycolytic proteins, such as PFK and HK1.